针对抗药性焦点的基因疗法的最新进展和挑战
1UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
Revue neurologique
|March 30, 2025
概括
基因疗法对耐药焦点具有前景. 本综述探讨了将这些治疗方法从动物模型转化为临床应用的挑战,重点是输送和剂量.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 的研究研究.
背景情况:
- 耐药焦点是一种重要的临床挑战,治疗选择有限.
- 基因疗法策略在临床前模型中显示出有前途,特别是对于叶.
- 几种基因治疗方法正在接近临床试验准备.
研究的目的:
- 审查与将的基因疗法从实验模型转化为人类临床试验相关的挑战.
- 确定基因治疗药物耐药焦点的开发和应用中的关键障碍.
主要方法:
- 对的临床前基因疗法研究的文献综述.
- 分析临床转化方面的挑战,包括促进者-转基因选择,剂量,输送和跨类型的适用性.
主要成果:
- 针对的基因疗法开发在选择适当的促销者-转基因组合方面面临障碍.
- 确定安全有效的剂量对于成功的临床转化至关重要.
- 最佳的输送方法和在不同病病因学上推断研究结果仍然是重大挑战.
结论:
- 对抗药性焦点的基因疗法的成功临床转化需要解决临床前临床进展的关键挑战.
- 需要进一步的研究来优化基因治疗策略,以便在患者中安全有效地使用.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
05:26Press Needle: A Traditional Chinese Medicine Therapy for Myopia Patients with Dry Eye
Published on: April 12, 2024
相关概念视频
Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
CRISPR
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced Short...
Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
